- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00729183
Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)
July 27, 2018 updated by: Merck Sharp & Dohme LLC
A Phase III Randomized, Placebo-Controlled Study to Evaluate the Effect of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety, and to Estimate the Effect of Odanacatib (MK-0822) on Bone Micro-architecture in Postmenopausal Women Treated With Vitamin D
This study will evaluate the safety and treatment effect of 50 mg odanacatib (MK-0822) with Vitamin D versus placebo with Vitamin D in postmenopausal women with low bone density.
The primary efficacy hypothesis is that odanacatib will increase aBMD at the lumbar spine compared to placebo at 12 months.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
214
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 85 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Participant has been postmenopausal for 3 years
- Participant has BMD t-score at the total hip, hip trochanter, femoral neck, or lumbar spine ≥ -1.5 but > -3.5
- Participant has 2 hips that are evaluable by dual-energy X-ray absorptiometry (DXA) and quantitative computed tomography (QCT), e.g. contain no hardware from orthopedic procedures
- Participant is ambulatory
Exclusion Criteria:
- Participant has had a previous hip fracture
- Participant has had >1 prior clinical vertebral fracture AND is a candidate for osteoporosis therapy
- Participant has been treated with oral bisphosphonates, strontium, parathyroid hormone (PTH) or other agents with an effect on bone
- Participant has had metabolic bone disorder other than osteoporosis
- Participant has renal stones, Parkinson's disease, multiple sclerosis (MS) or active parathyroid disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Odanacatib 50 mg
Participants receive 50 mg odanacatib and open-label 5600 IU vitamin D3 tablets once weekly for 24 months.
Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.
|
Odanacatib 50 mg tablets, taken orally once weekly for 24 months.
Other Names:
Vitamin D3 tablets (5600 IU) taken orally once weekly for 24 months.
Calcium supplement 500 mg tablet taken orally once daily (up to ~1200 mg total) for 24 months.
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Participants receive matching placebo to odanacatib and open-label 5600 IU vitamin D3 once weekly for 24 months.
Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.
|
Vitamin D3 tablets (5600 IU) taken orally once weekly for 24 months.
Calcium supplement 500 mg tablet taken orally once daily (up to ~1200 mg total) for 24 months.
Other Names:
Matching placebo tablets to odanacatib taken orally once weekly for 24 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline to Month 12 in Lumbar Spine Areal Bone Mineral Density (aBMD)
Time Frame: Baseline, 12 months
|
aBMD (g/cm^2) was measured by dual-energy X-ray absorptiometry (DXA) at the lumbar spine and mean BMD measurements from at least 3 evaluable lumbar spine vertebrae (L1-L4) were used.
If a vertebra was fractured at baseline or became fractured during the study, its BMD measurement was excluded from the analysis and the lumbar spine BMD was recalculated based on the three remaining vertebrae.
aBMD data was centrally evaluated and all areal BMD measurements included a longitudinal BMD correction factor as determined by the quality control center.
aBMD at the lumbar spine was assessed at the Screening visit (Baseline), Month 6, Month 12, and Month 24 for the repeated measures longitudinal Analysis of Covariates (ANCOVA) model, with percent change from baseline at Months 12 and 24 pre-specified to be reported as primary and secondary outcome measures, respectively.
|
Baseline, 12 months
|
Percentage of Participants That Experienced an Adverse Event (AE)
Time Frame: Up to ~14 days post study end (up to ~24 months)
|
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's products, whether or not considered related to the use of the product.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR's product was also an AE.
The percentage of participants that experienced at least one AE was reported for each treatment arm.
|
Up to ~14 days post study end (up to ~24 months)
|
Percentage of Participants That Discontinued Study Treatment Due to an AE
Time Frame: Up to ~14 days post study end (up to ~24 months)
|
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's products, whether or not considered related to the use of the product.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR's product was also an AE.
The percentage of participants that discontinued study treatment (different from discontinuation of the study) due to an AE was reported for each treatment arm.
|
Up to ~14 days post study end (up to ~24 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline to Month 24 in Lumbar Spine aBMD
Time Frame: Baseline, 24 months
|
aBMD (g/cm^2) was measured by DXA at the lumbar spine and mean BMD measurements from at least 3 evaluable vertebrae from L1 through L4 were used.
If a vertebra was fractured at baseline or became fractured during the study, its BMD measurement was excluded from the analysis and the lumbar spine BMD was recalculated based on the three remaining vertebrae.
aBMD data was centrally evaluated and all areal BMD measurements included a longitudinal BMD correction factor as determined by the quality control center.
aBMD at the lumbar spine was assessed at the Screening visit (Baseline), Month 6, Month 12, and Month 24 for the repeated measures longitudinal ANCOVA model, with percent change from baseline at Months 12 and 24 pre-specified to be reported as primary and secondary outcome measures, respectively.
|
Baseline, 24 months
|
Percent Change From Baseline in Total Hip aBMD
Time Frame: Baseline, 12 months, 24 months
|
aBMD (g/cm^2) data was measured by DXA at the total hip.
All measurements utilized the same hip and at least 2 vertebrae for all time points.
The left hip only was scanned.
If the left hip was unevaluable, then the right hip was scanned.
Once the appropriate leg was identified for scanning, it was used for all subsequent measurements.
aBMD data was centrally evaluated and all areal BMD measurements included a longitudinal BMD correction factor as determined by the quality control center.
aBMD at the total hip was assessed at the Screening visit (Baseline), Month 6, Month 12, and Month 24 for the repeated measures longitudinal ANCOVA model, with percent change from baseline at Months 12 and 24 pre-specified to be reported as secondary outcome measures.
|
Baseline, 12 months, 24 months
|
Percent Change From Baseline in Femoral Neck aBMD
Time Frame: Baseline, 12 months, 24 months
|
aBMD (g/cm^2) data was measured by DXA at the femoral neck (hip).
All measurements utilized the same hip and at least 2 vertebrae for all time points.
The left hip only was scanned.
If the left hip was unevaluable, then the right hip was scanned.
Once the appropriate leg was identified for scanning, it was used for all subsequent measurements.
aBMD data was centrally evaluated and all areal BMD measurements included a longitudinal BMD correction factor as determined by the quality control center.
aBMD at the femoral neck was assessed at the Screening visit (Baseline), Month 6, Month 12, and Month 24 for the repeated measures longitudinal ANCOVA model, with percent change from baseline at Months 12 and 24 pre-specified to be reported as secondary outcome measures.
|
Baseline, 12 months, 24 months
|
Percent Change From Baseline in Hip Trochanter aBMD
Time Frame: Baseline, 12 months, 24 months
|
aBMD (g/cm^2) data was measured by DXA at the hip trochanter.
All measurements utilized the same hip and at least 2 vertebrae for all time points.
The left hip only was scanned.
If the left hip was unevaluable, then the right hip was scanned.
Once the appropriate leg was identified for scanning, it was used for all subsequent measurements.
aBMD data was centrally evaluated and all areal BMD measurements included a longitudinal BMD correction factor as determined by the quality control center.
aBMD at the hip trochanter was assessed at the Screening visit (Baseline), Month 6, Month 12, and Month 24 for the repeated measures longitudinal ANCOVA model, with percent change from baseline at Months 12 and 24 pre-specified to be reported as secondary outcome measures.
|
Baseline, 12 months, 24 months
|
Percent Change From Baseline in Total Radius aBMD
Time Frame: Baseline, 12 months, 24 months
|
aBMD (g/cm^2) data was measured by DXA at the total radius (forearm).
aBMD data was centrally evaluated and all areal BMD measurements included a longitudinal BMD correction factor as determined by the quality control center.
aBMD at the total radius was assessed at the Screening visit (Baseline), Month 6, Month 12, and Month 24 for the repeated measures longitudinal ANCOVA model, with percent change from baseline at Months 12 and 24 pre-specified to be reported as secondary outcome measures.
|
Baseline, 12 months, 24 months
|
Percent Change From Baseline in Ultradistal Radius aBMD
Time Frame: Baseline, 12 months, 24 months
|
aBMD (g/cm^2) data was measured by DXA at the ultradistal radius (forearm).
aBMD data was centrally evaluated and all areal BMD measurements included a longitudinal BMD correction factor as determined by the quality control center.
aBMD at the ultradistal radius was assessed at the Screening visit (Baseline), Month 6, Month 12, and Month 24 for the repeated measures longitudinal ANCOVA model, with percent change from baseline at Months 12 and 24 pre-specified to be reported as secondary outcome measures.
|
Baseline, 12 months, 24 months
|
Percent Change From Baseline in Distal Radius aBMD
Time Frame: Baseline, 12 months, 24 months
|
aBMD (g/cm^2) data was measured by DXA at the one-third distal radius (forearm).
aBMD data was centrally evaluated and all areal BMD measurements included a longitudinal BMD correction factor as determined by the quality control center.
aBMD at the distal radius was assessed at the Screening visit (Baseline), Month 6, Month 12, and Month 24 for the repeated measures longitudinal ANCOVA model, with percent change from baseline at Months 12 and 24 pre-specified to be reported as secondary outcome measures.
|
Baseline, 12 months, 24 months
|
Percent Change From Baseline in Trabecular Volumetric Bone Mineral Density (vBMD) at Central Section of Spine (L1)
Time Frame: Baseline, 12 months, 24 months
|
Trabecular vBMD at the lumbar spine (L1) was measured by quantitative computed tomography (QCT).
All QCT-derived vBMD measurements were evaluated centrally (and possibly locally) for bone and soft tissue abnormalities.
Trabecular vBMD at the lumbar spine (L1) was assessed at the Screening visit (Baseline), Month 6, Month 12, and Month 24 for the repeated measures longitudinal ANCOVA model, with percent change from baseline at Months 12 and 24 pre-specified to be reported as secondary outcome measures.
|
Baseline, 12 months, 24 months
|
Percent Change From Baseline in Trabecular vBMD at Central Section of Spine (L2)
Time Frame: Baseline, 12 months, 24 months
|
Trabecular vBMD at the lumbar spine (L2) was measured by quantitative computed tomography (QCT).
All QCT-derived vBMD measurements were evaluated centrally (and possibly locally) for bone and soft tissue abnormalities.
Trabecular vBMD at the lumbar spine (L2) was assessed at the Screening visit (Baseline), Month 6, Month 12, and Month 24 for the repeated measures longitudinal ANCOVA model, with percent change from baseline at Months 12 and 24 pre-specified to be reported as secondary outcome measures.
|
Baseline, 12 months, 24 months
|
Percent Change From Baseline in Serum C-Terminal Telopeptides of Type 1 Collagen (s-CTx) Level
Time Frame: Baseline, 12 months, 24 months
|
s-CTx is a biochemical marker index of bone resorption.
s-CTx was measured via fasting blood draws at Baseline (Randomization), Month 6, Month 12, Month 18, and Month 24 for the repeated measures longitudinal ANCOVA model, with percent change from baseline at Months 12 and 24 pre-specified to be reported as secondary outcome measures.
S-CTx was analyzed using the log-transformed fraction from baseline using the per-protocol approach.
Data were back-transformed for presentation and geometric LS mean percent change from baseline was reported with 95% CI.
|
Baseline, 12 months, 24 months
|
Percent Change From Baseline in Serum N-Terminal Propeptides of Type 1 Collagen (s-P1NP) Level
Time Frame: Baseline, 12 months, 24 months
|
s-P1NP is a biochemical marker index of bone formation.
s-P1NP was measured via fasting blood draws at Baseline (Randomization), Month 6, Month 12, Month 18, and Month 24 for the repeated measures longitudinal ANCOVA model, with percent change from baseline at Months 12 and 24 pre-specified to be reported as secondary outcome measures.
s-P1NP was analyzed using the log-transformed fraction from baseline using the per-protocol approach.
Data were back-transformed for presentation and geometric LS mean percent change from baseline was reported with 95% CI.
|
Baseline, 12 months, 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Engelke K, Fuerst T, Dardzinski B, Kornak J, Ather S, Genant HK, de Papp A. Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women: results of a two-year placebo-controlled trial. J Bone Miner Res. 2015 Jan;30(1):30-8. doi: 10.1002/jbmr.2292.
- Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T, Engelke K, Recker R, Dardzinski B, Verbruggen N, Ather S, Rosenberg E, de Papp AE. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab. 2013 Feb;98(2):571-80. doi: 10.1210/jc.2012-2972. Epub 2013 Jan 21.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 2, 2008
Primary Completion (ACTUAL)
March 23, 2010
Study Completion (ACTUAL)
March 21, 2011
Study Registration Dates
First Submitted
August 4, 2008
First Submitted That Met QC Criteria
August 6, 2008
First Posted (ESTIMATE)
August 7, 2008
Study Record Updates
Last Update Posted (ACTUAL)
August 27, 2018
Last Update Submitted That Met QC Criteria
July 27, 2018
Last Verified
July 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Musculoskeletal Diseases
- Bone Diseases
- Bone Diseases, Metabolic
- Osteoporosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Gastrointestinal Agents
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Antacids
- Vitamin D
- Cholecalciferol
- Calcium
- Calcium, Dietary
- Calcium Carbonate
Other Study ID Numbers
- 0822-031
- 2008_539 (OTHER: Merck Registration Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporosis
-
Radius Health, Inc.CompletedOsteoporosis | Osteoporosis Risk | Osteoporosis, Postmenopausal | Osteoporosis Fracture | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of Vertebrae | Osteoporosis VertebralUnited States
-
Radius Health, Inc.CompletedOsteoporosis | Age Related Osteoporosis | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of VertebraeUnited States, Poland, Italy
-
Hoffmann-La RocheCompletedPostmenopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States, Puerto Rico
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceRecruitingPost Menopausal OsteoporosisFrance
-
AmgenCompletedPost Menopausal OsteoporosisFrance
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisSpain, South Africa, Germany, Mexico, United States, Canada, France, United Kingdom, Italy, Belgium, Australia, Poland, Denmark, Hungary, Czech Republic, Norway
-
Hoffmann-La RocheGlaxoSmithKlineCompletedPost Menopausal OsteoporosisFrance
-
Novartis PharmaceuticalsCompletedPost-menopausal OsteoporosisColombia, Belgium, Sweden, Hong Kong, United States, Hungary, Switzerland, Australia, Germany, Italy, Canada, Poland, Argentina, Thailand, Norway, New Zealand, France, Finland
Clinical Trials on Odanacatib
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCWithdrawn
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCWithdrawn
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedBreast Cancer | Metastatic Bone Disease